Source: Eur Respir J 2016; 48: 1503-1507
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio, Rosella Centis, Jan Willem Alffenaar, Jose A. Caminero, Marcos Abdo Arbex, Valentina Alarcon Guizado, Alena Aleksa, Simone Dore, Mina Gaga, Gina Gualano, Heinke Kunst, Marie-Christine Payen, Aurora Jazmín Roby Arias, Alena Skrahina, Ivan Solovic, Giorgia Sulis, Marina Tadolini, Alimuddin Zumla and Giovanni Battista Migliori for the International Carbapenem Study Group. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis. Eur Respir J 2016; 48: 1503-1507

Member's Comments

No comment yet.

Related content which might interest you: Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated Source: Eur Respir J , 49 (3) 1700081; DOI: 10.1183/13993003.00081-2017 Year: 2017 Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019 Year: 2020 Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015 Source: Eur Respir J , 49 (4)  1602309; DOI: 10.1183/13993003.02309-2016 Year: 2017 Shorter treatment duration for selected patients with multidrug-resistant tuberculosis Source: Eur Respir J 2011; 37: 227-230 Year: 2011 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700228; 10.1183/13993003.00228-2017 Year: 2017 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700463; 10.1183/13993003.00463-2017 Year: 2017 Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico Source: Eur Respir J, 51 (3) 1702267; 10.1183/13993003.02267-2017 Year: 2018 Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India Source: Eur Respir J 2012; 39: 956-962 Year: 2012 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018 Year: 2018 The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 2000224; 10.1183/13993003.00224-2020 Year: 2020 Short course of chemotherapy of multidrug resistant tuberculosis (MDR TB) Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016